CYP3A4 and pneumocystosis: Opportunistic infections of particular concern for patients taking BTK inhibitors include fungal infections with aspergillus fumigatus and Pneumocystis jirovecii pneumonia (PJP) given the potential for serious outcomes and the fact that the appropriate treatments for these infections involve strong CYP3A4 inhibitors [60,69].